<div id="readability-page-1"><p>Reynders McVeigh Capital Management LLC bought a new position in shares of  Novo Nordisk A/S (NYSE:NVO - Free Report) during the 2nd quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The fund bought 363,889 shares of the company's stock, valued at approximately $25,116,000.</p><div><p><span></span><span>Get <strong>Novo Nordisk A/S</strong> alerts:</span></p></div><ul><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p>Other institutional investors and hedge funds have also modified their holdings of the company. Revolve Wealth Partners LLC lifted its holdings in shares of  Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after purchasing an additional 200 shares in the last quarter.  Charles Schwab Investment Management Inc. boosted its position in shares of  Novo Nordisk A/S by 15.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 261,243 shares of the company's stock valued at $18,141,000 after acquiring an additional 35,329 shares during the period.  Kovitz Investment Group Partners LLC increased its stake in  Novo Nordisk A/S by 7.5% in the first quarter. Kovitz Investment Group Partners LLC now owns 74,182 shares of the company's stock valued at $5,151,000 after acquiring an additional 5,194 shares during the last quarter.  Horizon Investments LLC lifted its stake in  Novo Nordisk A/S by 117.4% during the first quarter. Horizon Investments LLC now owns 5,466 shares of the company's stock worth $380,000 after purchasing an additional 2,952 shares during the last quarter.  Finally, Aberdeen Group plc boosted its holdings in shares of  Novo Nordisk A/S by 7.9% in the 1st quarter. Aberdeen Group plc now owns 280,734 shares of the company's stock valued at $19,494,000 after purchasing an additional 20,565 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several analysts recently weighed in on NVO shares. Zacks Research downgraded Novo Nordisk A/S from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Wednesday, December 3rd. Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a research report on Monday, October 27th. They issued an &#34;underperform&#34; rating for the company. Sanford C. Bernstein upgraded Novo Nordisk A/S from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a report on Tuesday, September 9th. TD Cowen reduced their target price on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, August 19th. Finally, The Goldman Sachs Group decreased their price objective on Novo Nordisk A/S from $60.00 to $54.00 and set a &#34;buy&#34; rating for the company in a report on Friday, November 28th. One investment analyst  has rated the stock with a Strong Buy rating, six have issued  a Buy rating, twelve have assigned  a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Hold&#34; and a consensus price target of $53.33.</p><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p><b>Get Our Latest Analysis on NVO</b></p><h2>Novo Nordisk A/S Stock Down 0.3%</h2><p>NVO stock opened at $50.12 on Monday. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $223.79 billion, a PE ratio of 14.57 and a beta of 0.67. The stock's 50 day moving average is $50.86 and its 200-day moving average is $58.29. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $109.88. </p><ul><li>Down 45% Year-to-Date, Novo Nordisk Ignites a Price War</li></ul><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion.  Sell-side analysts expect that  Novo Nordisk A/S will post 3.84 EPS for the current fiscal year. </p><h2>Novo Nordisk A/S Company Profile</h2> (Free Report)<p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Novo Nordisk A/S</li><li>What is the S&amp;P/TSX Index?</li><li>3 Underrated Robotics Stocks Poised for Huge Gains</li><li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>P/E Ratio Calculation: How to Assess Stocks</li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Reynders McVeigh Capital Management LLC acquired 363,889 shares of Novo Nordisk A/S, valued at $25,116,000, during Q2. Institutional investors hold 11.54% of the stock. Analysts have mixed ratings: one "Strong Buy," six "Buy," twelve "Hold," and three "Sell." The stock opened at $50.12, with a market cap of $223.79 billion. Novo Nordisk reported Q3 earnings of $1.02 per share, beating estimates by $0.25, with revenue of $11.79 billion.</p>

Reynders McVeigh Capital Management LLC Acquires New Shares in Novo Nordisk A/S $NVO